rubella
RUBELLA
Rubella, also known as German measles or 3-day measles, is a mild often exanthematous disease of infants and children that is severe and associated with complications in adults. It is self-limiting disease associated with a characteristic maculopapular rash.
It is caused by a single-stranded RNA virus classified as a togavirus, genus Rubivirus.
Transmission is through airborne or droplets shed from respiratory secretions.
Highly communicable at the onset of the rash, however viral shedding may also occur 5-7 days before, to 5-7 days or more following appearance of the rash.
The incubation period is 14-21 days.

Rubella Management

Prevention

Rubella vaccine is available as a single-antigen preparation or combined w/ other vaccines [eg mumps & rubella (MMR), or also w/ varicella (MMRV)]

  • MMRV is approved for use in healthy children ≥1-12 yrs of age
  • Routine vaccination against rubella is recommended for all children ≥12 mth; second dose should be routinely given at 4-6 yrs of age
  • Children ≤12 yr w/o previous immunization should be given at least 1 dose of MMR or MMRV
  • May be effective, theoretically, as post-exposure prophylaxis if given w/in 3 days of exposure
  • Single antigen is not routinely recommended

Prevention for Exposed Pregnant Women

  • Counseling regarding the risks & benefits of termination of pregnancy should be off ered to susceptible pregnant women exposed to rubella

Post-exposure Prophylaxis

  • Immunoglobulin may be given if termination of pregnancy is not an option based on maternal predilection
    • May reduce the risk of clinical infection but may not give an assurance of prevention of fetal infection
    • Dose of 0.55 mL/kg IM may be given
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Apr 2019
Using preventive zinc and micronutrient powder supplementation does not appear to improve growth in children, a recent study has found.
Audrey Abella, 14 Oct 2020
Findings from the phase IIa T1GER study revealed the therapeutic potential of the monoclonal antibody golimumab for children and young adults with type 1 diabetes (T1D).
Roshini Claire Anthony, 28 Sep 2020

A 4-week course of amoxicillin-clavulanate in children with protracted bacterial bronchitis (PBB) does not improve cough resolution rates compared with a 2-week course, according to a study from Australia. However, the longer course may significantly extend time to first cough exacerbation.